CVRx, Inc. (CVRX) is a Minneapolis-based, commercial-stage medical device company whose flagship product, Barostim, delivers baroreflex activation therapy for heart failure. Following its third-quarter report, analysts sharply reduced their price targets. The five most recent targets reviewed are Craig-Hallum at $1.25 (Hold), Piper Sandler at $1.50 (Neutral), Lake Street at $1.50 (Hold), Canaccord Genuity at $2.00 (Hold, downgraded from Buy), and Cantor Fitzgerald at $5.00 (Overweight).
The arithmetic mean of these five targets is $2.25, with a wide range of $1.25 to $5.00. Four targets were set on November 6, 2026, in the immediate aftermath of earnings; Cantor Fitzgerald's $5.00 was last revised in August 2026 and had not been updated following the latest guidance cut, which helps explain the unusually wide spread.
Views are cautious rather than bullish. Canaccord's downgrade cited headwinds "increasingly outside its control" with "no clear timeline for relief." Piper Sandler pointed to misses on domestic units placed and active implanting centers. Cantor's Overweight rating stands as the notable exception, reflecting a more constructive long-term view of Barostim adoption.
The latest verified price is approximately $0.87 as of the November 6, 2026 close, after a decline of roughly 41% in a single session. Reaching the $2.25 central target implies upside of about 159%, which qualifies as a very large move. The shares now trade far below their 200-day moving average and near multi-year lows.
The company reported third-quarter revenue of $13.8 million, down 6.1% year over year and below estimates, with a GAAP EPS (earnings per share) loss of $0.52. Management lowered full-year 2026 revenue guidance to $56–57 million from $58–60 million and guided fourth-quarter revenue to $11.7–12.7 million, indicating the reset may not be complete. Reaching $2.25 would require a meaningful reversal of revenue momentum and a return of investor confidence in the commercial strategy.
Several factors could underpin a recovery. Gross margin held steady at 87%, and the company ended September with about $58.7 million in cash, which management estimates provides at least 18 months of runway. CVRx has secured two written Medicare Advantage coverage policies, including one from Humana, representing roughly 21% of Medicare Advantage covered lives. Enrollment in the BENEFIT-HF trial is running ahead of plan, and effective October 1 the national average inpatient payment rate rose to about $45,000.
Management also noted that sales-force turnover fell to its lowest level in more than two years, and five of nine U.S. regions were growing procedures by more than 20% on average — evidence that execution is stabilizing in more tenured territories.
The principal obstacle is reimbursement. The company's largest Medicare Advantage payer has slowed approvals dramatically: the 30-day approval rate fell to about 12% from a high of 83% in 2025, and the overall Medicare Advantage approval rate dropped to 51% from 60% in the second quarter. Some hospitals are pausing implants while they confirm payment across their payer mix, and at least one large health system has held more than a dozen approved patients for multiple quarters.
Physician-champion turnover and uneven field execution continue to weigh on implant growth, and U.S. revenue fell 4% while European revenue dropped 27% in the quarter. With no clear timeline for reimbursement relief and ongoing losses, valuation support remains limited.
The stock's sharp breakdown has left it trading near multi-year lows, well below its longer-term moving averages, which had been around $5 before the decline. The $1.00 round-number level and the lowest current analyst target of $1.25 now sit as nearby overhead reference points. A durable recovery would likely need to reclaim these levels before the broader $2.25 target comes into view.
Analyst price targets generally reflect a roughly 12-month research horizon, though specific horizons vary by firm. Investors should watch the next quarterly report for evidence that the weaker regions have stopped shrinking, that the largest payer's approval rates have stabilized, and that 2027 guidance shows a credible return to growth. Reimbursement developments, prior-authorization approval trends, analyst revisions, and cash-burn updates are all material to the target.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. Traders can use these signals to discover opportunities, monitor positions, and spot shifting trends more efficiently than scanning charts manually. For a stock as volatile as CVRX, an objective, signal-based lens can complement fundamental research and help keep decisions data-driven.
The $2.25 central target is the mean of five recent analyst targets across a wide $1.25–$5.00 range, and it would require a very large move of roughly 159% from the current price near $0.87. The bull case rests on high gross margins, a solid cash position, improving coverage, and early signs of sales-force stabilization. The bear case centers on persistent reimbursement delays, guidance cuts, and no clear timeline for relief. Given the disagreement among analysts and the magnitude of the reset, the path to $2.25 depends first on evidence that revenue has bottomed and that payer behavior is improving — conditions that remain unproven.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, CVRX has been closely correlated with STRRP. These tickers have moved in lockstep 67% of the time. This A.I.-generated data suggests there is a high statistical probability that if CVRX jumps, then STRRP could also see price increases.
| Ticker / NAME | Correlation To CVRX | 1D Price Change % | ||
|---|---|---|---|---|
| CVRX | 100% | -10.93% | ||
| STRRP - CVRX | 67% Closely correlated | +0.89% | ||
| AZTA - CVRX | 39% Loosely correlated | -1.15% | ||
| IRTC - CVRX | 35% Loosely correlated | -3.01% | ||
| TMCI - CVRX | 34% Loosely correlated | +2.09% | ||
| A - CVRX | 34% Loosely correlated | -1.27% | ||
More | ||||
| Ticker / NAME | Correlation To CVRX | 1D Price Change % |
|---|---|---|
| CVRX | 100% | -10.93% |
| Health Services category (239 stocks) | -1% Poorly correlated | -1.13% |
| Medical/Nursing Services category (138 stocks) | -1% Poorly correlated | -1.46% |